Ken Griffin Sellas Life Sciences Group, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 147,400 shares of SLS stock, worth $172,458. This represents 0.0% of its overall portfolio holdings.

Number of Shares

147,400

Previous 266,000 44.59%

Holding current value

$172,458

Previous $281,000 47.33%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.51 - $1.55 $10,056 - $30,562	19,718 New	19,718 $19,000
Q2 2023 Aug 14, 2023	BUY	$1.35 - $1.8 $4,268 - $5,691	3,162 New	3,162 $4,000
Q4 2022 Feb 14, 2023	SELL	$2.02 - $5.41 $210,453 - $563,640	-104,185 Reduced 96.86%	3,375 $7,000
Q3 2022 Nov 14, 2022	BUY	$2.1 - $3.38 $146,834 - $236,332	69,921 Added 185.77%	107,560 $217,000
Q2 2022 Aug 15, 2022	BUY	$2.14 - $4.15 $51,935 - $100,716	24,269 Added 181.52%	37,639 $84,000

Q1 2022 May 16, 2022	SELL	$4.73 - $7.18 $129,947 - $197,256	-27,473 Reduced 67.26%	13,370 $89,000
Q4 2021 Feb 14, 2022	SELL	$5.36 - $9.53 $8,822 - $15,686	-1,646 Reduced 3.87%	40,843 $225,000
Q3 2021 Nov 15, 2021	BUY	$8.21 - $10.53 $227,072 - $291,238	27,658 Added 186.49%	42,489 $389,000
Q2 2021 Aug 16, 2021	SELL	$7.19 - $13.71 $68,793 - $131,177	-9,568 Reduced 39.21%	14,831 $164,000
Q1 2021 May 17, 2021	BUY	$5.5 - $11.71 $134,194 - $285,712	24,399 New	24,399 $208,000
Q2 2020 Aug 14, 2020	SELL	$1.53 - $3.93 $29,761 - $76,446	-19,452 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.7 - $4.08 $33,068 - $79,364	19,452 New	19,452 $34,000

Others Institutions Holding SLS

# of Institutions

Shares Held

8.03M

Call Options Held

2.52M

Put Options Held

24.7K

View Full List

About SELLAS Life Sciences Group, Inc.

Ticker SLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,551,900
Market Cap $24M
Description
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...

More about SLS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account